The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis ...
3d
JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)
Ingelheim, GermanyApproval is based on results from Phase III FIBRONEER™-IPF trial, which showed statistically significant improvements in the ...
The Chosun Ilbo on MSN
Jaksade Approved: First New Pulmonary Fibrosis Drug in a Decade
A new drug to alleviate idiopathic pulmonary fibrosis, a condition where the lungs harden and make breathing difficult, has ...
The investigators hypothesized that AFM might be able to identify unique nanomechanical fingerprints (NMFs) in tissue samples ...
Avalyn will present four posters in conjunction with the PFF Summit 2025 Welcome Reception from 5-8 p.m. CT on Thursday, November 13, 2025.
The development could help scientists develop patient-specific treatments and one day offer a lab-grown lung transplant ...
MILAN ― Numerous unresolved questions surround progressive pulmonary fibrosis (PPF) treatment, according to Elisabeth Bendstrup, MD, PhD, a researcher and clinical professor in the Department of ...
VIENNA — Treatment with a novel lysophosphatidic acid receptor 1 (LPA1) antagonist was associated with significant changes in baseline biomarkers of disease in adults with pulmonary fibrosis, based on ...
UCSF researchers shed light on how cells under stress can change their identity in harmful ways, contributing to pulmonary ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shares sank 50% on Wednesday after the company reported interim Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback